Clinical Trials Browser

Interventional × Has results × spartalizumab × Clear all

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Uterine Cervical Neoplasms

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

NCT04581343 2025-05-04

PanCAN-SR1

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1 Terminated

79 enrolled 42 charts

Gastrointestinal

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT02325739 2024-10-21

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Phase 1/2 Completed

172 enrolled 33 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Phase 2 Terminated

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03484923 2024-06-18

PLATforM

Phase 2 Completed

196 enrolled 22 charts

Melanoma

NCT03291054 2024-06-11

Epacadostat and Pembrolizumab in Patients With GIST

Phase 2 Terminated

1 enrolled 1 chart

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT02829723 2024-01-18

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase 1/2 Terminated

192 enrolled 77 charts

Glioblastoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT03499899 2023-01-30

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Phase 2 Completed

88 enrolled 35 charts

Triple Negative Breast Neoplasms

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2 Completed

76 enrolled 14 charts

GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

122 enrolled 28 charts

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase 2 Completed

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

141 enrolled 58 charts

BreastDermatologicGastrointestinalGynecologic

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02955069 2021-04-12

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 2 Completed

116 enrolled 24 charts

Neoplasm Metastasis, Neuroectodermal Tumors, Primitive

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms

NCT01313416 2019-07-10

Gemcitabine and CT-011 for Resected Pancreatic Cancer

Phase 2 Terminated

2 enrolled 5 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01420965 2019-07-10

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

Phase 2 Terminated

7 enrolled 7 charts

Prostatic Neoplasms

NCT02331368 2018-07-27

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Phase 2 Completed

32 enrolled 8 charts

Multiple Myeloma